rt—PA联合必存静脉溶栓治疗急性脑梗死的疗效观察(1)
【摘要】 目的：探讨rt-PA静脉溶栓联合必存治疗急性脑梗死患者的临床疗效。方法：选取2010年1月-2013年12月笔者所在医院收治的200例急性期脑梗死患者作为研究对象，按照随机数字表法将其分为A、B、C、D组各50例。其中A组给予rt-PA静脉溶栓联合必存治疗，B组给予rt-PA静脉溶栓加常规治疗，C组给予必存加常规治疗，D组仅给予常规治疗，14 d为一疗程，观察比较四组患者的临床疗效。结果：经治疗后，A组的总有效率为96.0%(48/50)，明显高于其他三组，差异均有统计学意义(P<0.05)。B组和C组的总有效率分别为84.0%(42/50)和66.0%(33/50)，均明显高于D组的46.0%(23/50)，且B组的总有效率明显高于C组，差异均有统计学意义(P<0.05)。结论：早期急性脑梗死患者应用rt-PA静脉溶栓联合必存治疗具有安全性和有效性，能最大限度改善患者预后，值得临床应用和推广。
【关键词】 急性脑梗死； rt-PA； 必存； 静脉溶栓
, 百拇医药
中图分类号 R743.33 文献标识码 A 文章编号 1674-6805(2014)35-0003-02
【Abstract】 Objective：To investigate the clinical efficacy of rt-PA for intravenous thrombolysis combined with Edaravone in the treatment of acute cerebral infarction.Method：200 patients with acute cerebral infarction in our hospital from January 2010 to December 2013 were selected，they were divided into the group A，B，C and D according to the random number table method，50 cases in each group.The group A was given rt-PA for intravenous thrombolysis combined with Edaravone，the group B was given rt-PA for intravenous thrombolysis combined with conventional treatment，the group C was given Edaravone and conventional treatment，the group D was only given conventional treatment.The clinical efficiency of four groups were compared after 14 days treatment.Result：After treatment，the total effective rate of group A was 96.0%(48/50)，it was significantly higher than the other three groups，the differences were statistically significant(P<0.05).The total effective rate of group B and group C were 84.0%(42/50) and 66.0%(33/50)，respectively，which were significantly higher than 46.0%(23/50) of group D，and the total effective rate of group B was significantly higher than group C，the differences were statistically significant(P<0.05).Conclusion：Application of rt-PA for intravenous thrombolysis combined with Edaravone in the treatment of early acute cerebral infarction patients has the safety and effectiveness，can improve the prognosis of patients to the maximum extent，is worthy of clinical application and promotion.
, 百拇医药
【Key words】 Acute cerebral infarction； rt-PA； Edaravone； Intravenous thrombolysis
脑卒中是现代工业化国家第三大死亡原因，在全球范围内致残率最高的最常见的疾病，脑梗死是最主要的疾病种类，我国的脑梗死占脑卒中的80%，发病主要是由于突发血栓或其他栓子栓塞血管导致局部脑组织突然缺乏氧和糖化物，尽管其发生过程有很多不同的机制，越来越多的研究表明为缺血损伤和炎症损伤所致[1-3]。针对缺血损伤，Astrup等提出缺血半暗带理论，随着缺血时间延长和缺血程度增加，脑实质中间坏死区逐渐扩大，缺血半暗带区逐渐缩小，造成细胞膜脂质过氧化，脑部神经细胞损伤和丧失相关功能[4]。目前，溶栓治疗是使血管再通的主要手段之一，可迅速恢复血供、挽救缺血半暗带，已成为治疗超早期急性脑梗塞的主要方法之一[5]。本研究对2010年1月-2013年12月笔者所在医院收治的50例急性脑梗死患者应用重组组织型纤溶酶原激活剂(rt-PA)联合必存静脉溶栓治疗，取得了满意的疗效，现将结果报告如下。, http://www.100md.com(陈春燕 张燕 陆学胜)
【关键词】 急性脑梗死； rt-PA； 必存； 静脉溶栓
, 百拇医药
中图分类号 R743.33 文献标识码 A 文章编号 1674-6805(2014)35-0003-02
【Abstract】 Objective：To investigate the clinical efficacy of rt-PA for intravenous thrombolysis combined with Edaravone in the treatment of acute cerebral infarction.Method：200 patients with acute cerebral infarction in our hospital from January 2010 to December 2013 were selected，they were divided into the group A，B，C and D according to the random number table method，50 cases in each group.The group A was given rt-PA for intravenous thrombolysis combined with Edaravone，the group B was given rt-PA for intravenous thrombolysis combined with conventional treatment，the group C was given Edaravone and conventional treatment，the group D was only given conventional treatment.The clinical efficiency of four groups were compared after 14 days treatment.Result：After treatment，the total effective rate of group A was 96.0%(48/50)，it was significantly higher than the other three groups，the differences were statistically significant(P<0.05).The total effective rate of group B and group C were 84.0%(42/50) and 66.0%(33/50)，respectively，which were significantly higher than 46.0%(23/50) of group D，and the total effective rate of group B was significantly higher than group C，the differences were statistically significant(P<0.05).Conclusion：Application of rt-PA for intravenous thrombolysis combined with Edaravone in the treatment of early acute cerebral infarction patients has the safety and effectiveness，can improve the prognosis of patients to the maximum extent，is worthy of clinical application and promotion.
, 百拇医药
【Key words】 Acute cerebral infarction； rt-PA； Edaravone； Intravenous thrombolysis
脑卒中是现代工业化国家第三大死亡原因，在全球范围内致残率最高的最常见的疾病，脑梗死是最主要的疾病种类，我国的脑梗死占脑卒中的80%，发病主要是由于突发血栓或其他栓子栓塞血管导致局部脑组织突然缺乏氧和糖化物，尽管其发生过程有很多不同的机制，越来越多的研究表明为缺血损伤和炎症损伤所致[1-3]。针对缺血损伤，Astrup等提出缺血半暗带理论，随着缺血时间延长和缺血程度增加，脑实质中间坏死区逐渐扩大，缺血半暗带区逐渐缩小，造成细胞膜脂质过氧化，脑部神经细胞损伤和丧失相关功能[4]。目前，溶栓治疗是使血管再通的主要手段之一，可迅速恢复血供、挽救缺血半暗带，已成为治疗超早期急性脑梗塞的主要方法之一[5]。本研究对2010年1月-2013年12月笔者所在医院收治的50例急性脑梗死患者应用重组组织型纤溶酶原激活剂(rt-PA)联合必存静脉溶栓治疗，取得了满意的疗效，现将结果报告如下。, http://www.100md.com(陈春燕 张燕 陆学胜)